Bristol-Myers Squibb Co
BMY:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 43.30 | 0.53 1.24% | 3.23% | 11,130,086 | 13.2M |
Market data is delayed by at least 20 minutes.
Latest News Headlines for Bristol-Myers Squibb Co
Bristol-Myers Squibb Announces Intention to Voluntarily Delist Preferred Stock
NEW YORK--(BUSINESS WIRE)--May 16, 2013--
Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has notified the New York Stock Exchange ("NYSE") of its intention to voluntarily delist its $2 Convertible Preferred Stock (the "Preferred Stock") from the NYSE.
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
NEW YORK--(BUSINESS WIRE)--May 15, 2013--
Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference at 7 p.m. EDT (6 p.m. CDT) on Sunday, June 2, 2013, to review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented at the meeting, with a focus on the immuno-oncology portfolio, and address inquiries from investors and analysts.
Bristol-Myers Squibb Advances Leadership Position -4-
View more recent headlines
fatigue (91% vs 79%), nausea (64% vs 50%), dry skin (57% vs 15%),
pain-other (59% vs 37%), and constipation (53% vs 38%). The most common
grade 3/4 adverse reactions (>=10%) included: fatigue (31% vs 29%),
Company Background
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles.
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 42.99 | Previous Close 42.77 |
Day High 43.43 | Day Low 42.70 |
52wk High/Date 45.59 / 5/15/2013 | 52wk Low/Date 30.64 / 11/15/2012 |
% off 52wk High -5.02% | % off 52wk Low 41.32% |
Beta (5 Yr) 0.4 | Market Capitalization 71.1B |
Shares Outstanding 1.6B | Volatility Avg 19.01 |
EPS(TTM) 0.88 | P/E Ratio 49.4x |
Dividend Announcement 3/7/2013 | Dividend Yield 3.23% |
Ex-Date 4/3/2013 | Date of Record 4/5/2013 |
Payable 0.35 - QRTR | Payable Date 5/1/2013 |
Last Trade as of 5/17/2013 4:00 PM ET | |
BMY Bristol-Myers Squibb Co vs. Peers
| Peers | |
|---|---|
BMY Bristol-Myers Squibb Co | 32.86% |
Johnson & Johnson | 25.66% |
Pfizer Inc. | 15.47% |
Merck & Co., Inc. | 12.34% |
BMY Bristol-Myers Squibb Co | 3.23% |
Johnson & Johnson | 3.00% |
Pfizer Inc. | 3.31% |
Merck & Co., Inc. | 3.74% |
BMY Bristol-Myers Squibb Co | 1.24% |
Johnson & Johnson | 0.73% |
Pfizer Inc. | -0.99% |
Merck & Co., Inc. | -0.82% |